Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: Posthumous sperm donation is technically feasible and morally acceptable, the specialists said in a review published in the Journal of Medical Ethics on Tuesday. They argue it should be seen like organ and other tissue donations as a way of relieving the suffering of others. While infertility is not life-threatening, said Nathan Hodson of Britain’s Leicester University and Joshua Parker of Britain’s Wythenshawe Hospital in Manchester, it causes great suffering and could be said to be a form of illness. “If it is morally acceptable that individuals can donate their tissues to relieve the suffering of others in ‘life enhancing transplants’ for diseases ... we see no reason why this cannot be extended to other forms of suffering like infertility, which may or may not also be considered a disease,” they said. Such a move would raise questions about consent and family permissions for posthumous donations, Parker and Hodson said, and there would also be concerns about anonymity of the donor. Britain has a shortage of donor sperm, while demand is high, and increasing, the experts said. They cited government data showing that an estimated 4,000 samples are imported to Britain each year from the United States, and 3,000 from Denmark, as well as more from other European Union countries. Sperm can be collected after death either through electrical stimulation of the prostate gland or with surgery. It can then be frozen and stored until required. Parker and Hodson cited studies showing that sperm harvested from dead men can result in healthy pregnancies and children with normal health and development, even when the sperm is retrieved 48 hours after death. Other medical experts said the analysis raised issues that need to be resolved. “Further discussion is needed to understand whether people who need to use donor sperm would even want to use the sperm of a deceased donor,” said Sarah Norcross, director of the Progress Educational Trust. “It is also vital to seek the opinions of donor-conceived people about what they think the impact would be of never being able to meet the donor.” Claim: Posthumous sperm donation should be allowed, say UK experts.

Answer: Men in Britain should be allowed to donate sperm after they die to meet growing demand from couples seeking fertility treatment, medical experts say.


Question: Paragraph: Although Pfizer continues to test the drug, called dacomitinib, in another Phase III study, hopes for its success have now largely faded, according to ISI Group analyst Mark Schoenebaum. “We believe consensus expectations (for the drug) will be close to zero given today’s readout” of unsuccessful trial results, Schoenebaum said in a research note. In one of the failed trials, called ARCHER 1009, patients given Pfizer’s once-daily pill did not show improved survival without the cancer worsening, compared with Roche Holding AG’s widely used Tarceva (erlotinib). Tarceva is the current standard of care in patients with mutated forms of a protein called Epidermal Growth Factor Receptor (EGFR). The protein plays a role in normal regulation of cell growth, but when mutated is believed to cause cells to proliferate and thereby help spur various types of cancer. Dacomitinib is designed to block several types of Epidermal Growth Factor receptors, while Tarceva and similar treatments for lung cancer target only one type of receptor. Cowen and Co had forecast annual sales of $500 million by 2020 for dacomitinib, if it were approved for lung cancer. That would make it a moderate-sized product for Pfizer, the largest U.S. drugmaker, which has annual revenue of $50 billion. Schoenebaum said there has been little investor interest in the drug and that Wall Street had expected it to generate annual sales of only $300 million by 2018. The second failed trial, named BR.26, involved patients that previously had failed to benefit from chemotherapy as well as from treatment with an EGFR inhibitor. Overall survival of patients taking the Pfizer drug was not prolonged in the study, compared with patients given a placebo. Pfizer said adverse events seen with dacomitinib were consistent with those seen in smaller earlier studies. In the meantime, Pfizer said dacomitinib is also being tested in a third late-stage trial, called ARCHER 1050, among patients with advanced non-small cell lung cancer who have not received prior treatment. The study will compare dacomitinib with Iressa (gefitinib), an EGFR inhibitor sold by AstraZeneca Plc. Results from that study are expected in 2015. Pfizer shares were little changed in morning trading on the New York Stock Exchange. Claim: Pfizer lung cancer drug fails in two large studies.

Answer: Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the most common form of the disease.


Question: Paragraph: In the Cairo working class neighborhood of Basateen, dozens line up outside a decades-old herbal spice shop with pyramid-shaped stacks of jars on display, filled with everything from honey and ginger to camel’s hay. Apothecaries say there has been a roughly 70-80 percent increase in sales of their wares since a series of harsh economic reforms hit supplies of conventional medicines and increased the cost of some generic and even life-saving drugs. The government said on Thursday those price rises could reach as high as 15 percent for domestically-produced medicines and 20 percent for imports. Store owner Samy al-Attar - whose last name is Arabic for apothecary - says a knowledgeable apothecary can find substitutes for drugs treating almost all non-terminal illnesses. Just like pharmacies, the walls inside al-Attar’s store are lined with drawers and containers. But rather than drugs, they hold herbs, each said to have its own unique healing property. Customers crowd outside the shop window, as staff dash around the tiny interior, choosing from a variety of textures and colors, filling clear plastic bags with orders. Customers explain their symptoms and Al-Attar produces a concoction of spices and herbs - with a more affordable price tag then at the conventional chemists. Local spices and herbs cost between 5 and 10 Egyptian pounds ($0.27-0.54) per kilogram. ($1 = 18.5000 Egyptian pounds) Claim: As drug supplies run short, Egyptians turn to herbal remedies.

Answer:
In an economic crisis that has led to a shortage of medicines, Egyptians are skipping trips to drug stores and instead turning  to herbal remedies to treat every-day illnesses.